Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological advances, other innovative biologics, such as...

Full description

Bibliographic Details

Published in:	mAbs
Main Authors:	HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Subjects:	Biobetter biologic biosimilar CT-P13 infliximab innovative biologics
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2020.1868078